Evaluating Lenti-HPV-07 Immunotherapy for HPV-Related Cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety and efficacy of Lenti-HPV-07, a new immunotherapy treatment for patients with HPV-related cervical or oropharyngeal cancers. Participants will be divided into two groups based on their cancer type: those with recurrent or metastatic cancer and those newly diagnosed with locally advanced cancer. The study will involve administering multiple injections of the treatment and will include follow-up visits for up to one year to monitor patient outcomes and immune responses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* histologically confirmed invasive HPV-related oropharyngeal or cervical cancer
* ECOG performance status of 0 or 1
* adequate hepatic, renal, pulmonary, and bone marrow/hematological function

Exclusion Criteria:

\- with seropositivity for HIV, active hepatitis C virus (HCV) infection, or hepatitis B (HBV) infection

Where it's running

• Florida Cancer Specialists (from Sarah Canon research Institute)
  Orlando, Florida, United States Recruiting
• Tampa General Hospital
  Tampa, Florida, United States Recruiting
• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting
• Oklahoma Cancer Specialists and Research Institute, LLC
  Tulsa, Oklahoma, United States Recruiting

Study contacts

• Study coordinator: Anastasia DEMIDOV
• Email: ademidova@theravectys.com
• Phone: +33

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Immunotherapy using E7 TCR-T cells for HPV-related cancers

  This study is testing a new immunotherapy using E7 TCR-T cells to see if it can help people with advanced HPV-related cancers like cervical and throat cancer feel better and improve their health.

  Recruiting at 3 sites Phase 2 Rutgers, The State University of New Jersey · Bethesda, Maryland and 2 other locations · NCT05686226

• Intranasal WSK-IM05 vaccine plus tislelizumab before surgery for HPV‑positive oropharyngeal cancer

  This phase I trial will see if an intranasal WSK‑IM05 vaccine given with the PD‑1 drug tislelizumab before surgery helps people with resectable HPV‑positive oropharyngeal cancer.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07565740

• Lowering nodal and primary tumor radiation dose in HPV-positive oropharyngeal cancer

  This phase II study tests whether reducing radiation doses to regions without visible cancer, while keeping the main tumor dose the same, can treat HPV-positive OPSCC with fewer side effects.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07497607

• Selective dose reduction of neck radiation in HPV-associated oropharyngeal cancer

  This trial tests whether lowering radiation doses to certain neck lymph nodes or gross disease areas is safe and can reduce side effects for adults with HPV-related oropharyngeal cancer.

  Recruiting at 4 sites Phase 2 University of Maryland, Baltimore · Baltimore, Maryland and 3 other locations · NCT07418034

• CUE-101 with pembrolizumab for locally advanced HPV‑16 positive oropharyngeal cancer

  This trial tests whether CUE-101 alone or combined with pembrolizumab before definitive therapy helps people with newly diagnosed, locally advanced HPV‑16 positive oropharyngeal cancer who are HLA‑A*02:01 positive.

  Recruiting Phase 2 Yale University · New Haven, Connecticut · NCT07172256

• Sacituzumab govitecan plus cetuximab for recurrent or metastatic head and neck squamous cell cancer

  This trial will test whether combining sacituzumab govitecan with cetuximab works and is safe for people whose head and neck squamous cell cancer has returned or spread after prior immunotherapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07063212

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.